Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 22,217 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Acute Respiratory Failure
Interventions: Early ICU rehabilitation strategies, Usual Care; Other
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetic Retinopathy
Interventions: Placebo, RG7774; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more

Conditions: Stress, Anxiety, Autonomic Dysregulation, Acoustic Stimulation, Hyperarousal, Health Personnel
Interventions: Cereset Research; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 100 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pain
Interventions: Biofeedback Training; Behavioral
Lead sponsor: University of Tulsa; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Psoriasis
Interventions: IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion, IDP-118 Vehicle Cream; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 14
States / cities: Encino, California • Orange Park, Florida • Pinellas Park, Florida + 10 more

Conditions: Chronic Obstuctive Pulmonary Disease
Interventions: Bronchoscopy; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: ADHERE; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 21 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Jackson, Michigan • Port Huron, Michigan

Conditions: Diabetes Mellitus, Vitamin D Deficiency
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: Ascension Health; Industry
Eligibility: 34 Years to 69 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Ridge Preservation, Bone Regeneration
Interventions: Socket preservation control, Socket preservation experimental; Procedure
Lead sponsor: Harvard School of Dental Medicine; Other
Eligibility: 20 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Thrombocytopenia Related to Chronic Liver Disease
Interventions: Avatrombopag, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Preterm Birth
Interventions: Unconditional Cash Transfer (High-Value), Unconditional Cash Transfer (Low-Value); Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Biliary Cirrhosis
Interventions: ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Jacksonville, Florida • Miami, Florida • Naples, Florida + 3 more

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: ADX-038, Placebo; Drug
Lead sponsor: ADARx Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 21
States / cities: Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 18 more

Conditions: Polycystic Ovary Syndrome
Interventions: Flutamide, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Oppositional-Defiant Disorder
Interventions: Parent management training (PMT), Collaborative problem solving (CPS), Waitlist control; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 8 Years to 14 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Diabetes or With New Hyperglycemia
Interventions: Glucommander, Standard insulin infusion algorithm; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Atlanta, Georgia • Memphis, Tennessee • Seattle, Washington

Conditions: Myasthenia Gravis
Interventions: RVT-1401, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 15
States / cities: Mobile, Alabama • Phoenix, Arizona • Carlsbad, California + 12 more

Conditions: Spondylitis, Ankylosing
Interventions: CC-99677, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 16
States / cities: Flagstaff, Arizona • Gilbert, Arizona • Phoenix, Arizona + 13 more

Conditions: Healthy
Interventions: VGX-1027; Drug
Lead sponsor: VGX Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Inflammatory Bowel Disease, Crohn Disease
Interventions: Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 20 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 13 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Exenatide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida • Orlando, Florida

Conditions: Ebola Hemorrhagic Fever
Interventions: AVI-7537, Normal Saline Solution (NSS); Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Suicide, Depressive Disorder, Major, Anxiety Disorders, Suicidal Ideation, Suicidal Impulses
Interventions: Standard of Care, Crisis Intervention, Wraparound Services; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 10 Years to 18 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Cereset Research Long-Term Healthcare Worker Study

Biofeedback Training to Control Pain Processing

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Lung Microbiome and Inflammation in Early COPD

An Intervention to Promote Oral Agent Adherence and Symptom Management: ADHERE

Effect of Vitamin D Supplementation on Hemoglobin A1c

Socket Preservation Procedure Studying Soft and Hard Tissue Outcomes

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

COIN: A Pilot Study of Cash Transfers to Improve Outcomes in Low-Income Preterm Neonates and Their Families

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome

Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder

Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

Multiple-Dose Study of VGX-1027 in Healthy Subjects

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers

Promote Access to Stop Suicide: Comparison of Follow up Services for Youth at Risk for Suicide